IL-17 Receptor Signaling Inhibits C/EBPbeta by Sequential Phosphorylation of the Regulatory 2 Domain
Overview
Physiology
Science
Authors
Affiliations
Interleukin-17 (IL-17), the hallmark cytokine of T helper 17 (T(H)17) cells, signals through a distinct receptor subclass, yet little is known about the mechanisms involved. IL-17 activates the expression of target genes through the actions of the transcription factors nuclear factor kappaB (NF-kappaB), CAAT enhancer binding protein delta (C/EBPdelta), and C/EBPbeta. The adaptor proteins tumor necrosis factor receptor-associated factor 6 (TRAF6) and Act1 are upstream of NF-kappaB and C/EBPdelta, but the regulation of C/EBPbeta remains undefined. Here, we show that IL-17 signaling led to phosphorylation of two sites in the regulatory 2 domain of C/EBPbeta in a sequential, interdependent fashion. The first was rapid and dependent on extracellular signal-regulated kinase (ERK), whereas the second was dependent on the activity of glycogen synthase kinase 3beta (GSK-3beta). These pathways were mediated by distinct subdomains within IL-17 receptor A (IL-17RA). Whereas phosphorylation of threonine 188 (Thr188) was mediated by the previously identified SEF/IL-17R homology domain-Toll-IL-1R-like loop (SEFIR-TILL), phosphorylation of Thr179 occurred through a newly characterized motif located in the distal tail of IL-17RA. Phosphorylated C/EBPbeta mediated a negative signal, because blocking ERK and GSK-3beta increased expression of IL-17 target genes and a C/EBPbeta-Thr188 mutant enhanced activation of a C/EBP-dependent reporter. Overexpression of GSK-3beta inhibited IL-17-induced activation of a C/EBP-dependent reporter, and Thr179 of C/EBPbeta was not phosphorylated in GSK-3beta-deficient cells. Thus, IL-17 triggered the dual phosphorylation of C/EBPbeta, which inhibited the expression of proinflammatory genes. This detailed dissection is the first for the IL-17-mediated C/EBP pathway and the first known example of a negative signal mediated by IL-17RA.
The role of immunity in insulin resistance in patients with polycystic ovary syndrome.
Zhang Q, Yang Z, Ou X, Zhang M, Qin X, Wu G Front Endocrinol (Lausanne). 2025; 15:1464561.
PMID: 39911236 PMC: 11797073. DOI: 10.3389/fendo.2024.1464561.
Hendrix E, Sha J, Kilgore P, Neil B, Verma A, Chopra A Vaccines (Basel). 2025; 12(12.
PMID: 39772023 PMC: 11680114. DOI: 10.3390/vaccines12121361.
C/EBPδ Mediates Immunity to Renal Autoinflammatory Disorders in a Stage-specific Manner.
Dey I, Li Y, Taylor T, Peroumal D, Asada N, Panzer U J Immunol. 2024; 213(6):767-778.
PMID: 39082925 PMC: 11371505. DOI: 10.4049/jimmunol.2400124.
The RNA binding protein Arid5a drives IL-17-dependent autoantibody-induced glomerulonephritis.
Li Y, Vyas S, Mehta I, Asada N, Dey I, Taylor T J Exp Med. 2024; 221(9.
PMID: 39058386 PMC: 11284280. DOI: 10.1084/jem.20240656.
Act1 drives chemoresistance via regulation of antioxidant RNA metabolism and redox homeostasis.
Hong L, Herjan T, Chen X, Zagore L, Bulek K, Wang H J Exp Med. 2024; 221(7).
PMID: 38861022 PMC: 11167376. DOI: 10.1084/jem.20231442.